イムノジェネテクス株式会社

ImmunoGeneTeqs provides inflammation/immune disease control methods based on innovative gene analysis technology.

Based based in Tokyo, Japan, イムノジェネテクス株式会社 works in medtech.

Profile

"ImmunoGeneTeqs is a Medtech company specializing in inflammation and immune disease control methods based on innovative gene analysis technology. Offering a range of next-generation sequencing services, including single-cell RNA-Seq and T-cell repertoire analysis using the BD Rhapsody Express system and proprietary TAS-Seq method for high-sensitivity cDNA amplification. Single-cell RNA-Seq allows for the study of individual cell behavior within complex tissues, providing insights into subpopulation responses to the environment. Integrating single-cell RNA-Seq with TCR repertoire analysis enables simultaneous analysis of gene expression and TCRα/β pair sequences, facilitating the identification of promising T-cell clones based on their properties and frequencies. With services like minimal sample RNA-Seq and TCR repertoire analysis, ImmunoGeneTeqs supports the detection of disease-related T cells, analysis of treatment-induced changes, and specific response analysis to infection vaccines. Additionally, the company offers sequencing-only analysis services for libraries provided by clients, ensuring comprehensive and tailored solutions for diverse research needs."

Its activity falls under medtech; the profile below is assembled from public directory data.

The company is recorded as being based in Tokyo, Japan.

Its current recorded stage is Plug and Play portfolio startup.

Website: immunogeneteqs.com/index.html